Navigation Links
Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
Date:2/25/2008

MELBOURNE, Australia, Feb. 26 /PRNewswire/ -- Bionomics Limited (ASX: BNO) today announced the initiation of treatment for the first patient in the Phase I trial of its anti-cancer drug, BNC105.

The BNC105 Phase I clinical trial involves treatment of patients with advanced cancer. Patients will be treated with BNC105 on days 1 and 8 of a 21 day cycle, over two cycles. The trial will be conducted at clinical sites within the Cancer Trials Australia network at the Royal Melbourne Hospital, the Peter MaCallum Cancer Centre and the Western Hospital in Melbourne.

Dr. Deborah Rathjen, CEO and Managing Director of Bionomics hailed the commencement of the Phase I trial as a significant milestone for the Company.

"We are excited to commence our trial of BNC105 and to announce our first patient has begun treatment," Dr Rathjen commented. "We will provide regular updates as we move through the trial, and I look forward to updating shareholders on our progress."

The primary objective for this trial is the evaluation of the safety and tolerability of BNC105. The results obtained from this trial will enable the identification of an appropriate dose of BNC105 for subsequent trials. Further objectives include, the evaluation of BNC105 pharmacokinetics and its activity against tumour vasculature and tumour growth.

BNC105 is a new type of anti-cancer drug called a Vascular Disruption Agent (VDA) which blocks the blood supply to a solid tumour, effectively "starving" the tumour of nutrients. Pre-clinical data indicates that BNC105 has a dual mechanism of action with the ability to not only block the supply of nutrients to the tumour but also to directly destroy cancer cells. In addition, BNC105 is retained in the tumour at high levels for an extended period of time, enhancing its' anti-cancer effect.

Although VDAs have strong potential for use in combination with traditional cancer treatment options, including chemotherapy, preclinical
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... N.J., Oct. 4 Medco Health Solutions, Inc. ... its third-quarter 2010 financial results in a press ... 2, 2010.   (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... management will hold a conference call at 8:30 ...
... VIVUS, Inc. (Nasdaq: VVUS ) today ... agreement with Meda - an international specialty pharma company ... erectile dysfunction (ED).  Under the agreement, Meda will acquire ... MUSE patents, existing inventory and the manufacturing facility located ...
Cached Medicine Technology:Medco Announces Date for Third-Quarter 2010 Financial Results 2VIVUS Announces Sale of MUSE Assets to Meda 2VIVUS Announces Sale of MUSE Assets to Meda 3
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... basketball court and goal on Live with Regis and Kelly. , ... ... California was honored by Live with Regis and Kelly,s 2009 Mom,s Dream ... there to make the Kilbert,s dream come true with a brand new ...
... People to Join Denim Day on October 2, To Support ... 8 Emmy Award-winning actress Christina Applegate , star ... returns as the 2009 ambassador for Lee National Denim Day, ... benefiting the Women,s Cancer Programs of the Entertainment Industry Foundation ...
... experience complications, study finds , , FRIDAY, May 8 (HealthDay ... other racial group to suffer serious complications after angioplasty ... reasons for these worse outcomes aren,t clear. , , That,s ... average age 57, who had a percutaneous coronary intervention ...
... Chairman of the Board of Directors for Intelligent Hospital ... Erik Hansen as Chief Executive Officer, effective May 11, ... McGarry held the dual positions of Chairman of the ... from a research and development culture into a highly ...
... Joe and Sue Paterno in New York City ... CHESTER, Pa., May 8 The Charcot-Marie-Tooth Association,s second annual ... Sue Paterno for a lifetime of achievement raised a record ... New York City on April 29. Proceeds earned from event ...
... early stage breast cancer patients has shown that a molecule ... as accurate as current techniques, but faster, more specific and ... biology to enter the operating room for lymph node detection," ... at the UC San Diego School of Medicine and the ...
Cached Medicine News:Health News:VersaCourt's Basketball Court Makes a Mom's Dream Come True 2Health News:VersaCourt's Basketball Court Makes a Mom's Dream Come True 3Health News:Christina Applegate Returns as the 2009 Lee National Denim Day Ambassador 2Health News:Christina Applegate Returns as the 2009 Lee National Denim Day Ambassador 3Health News:Christina Applegate Returns as the 2009 Lee National Denim Day Ambassador 4Health News:Racial Disparity Seen in Angioplasty Outcomes 2Health News:Charcot-Marie-Tooth Association's 'Honor a Star. Be a Star.' Gala Generates Over $350,000 for CMT Research 2Health News:New technique may help detect potential breast cancer spread 2
Head-worn Loupe G3, Galilean teleloupe system....
... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
... The XL Advantage delivers higher magnification ... a crisp, true image, even at the ... to edge clarity and precise color rendition ... treated with an anti-reflective coating produce a ...
... delivers higher magnification for advanced surgical procedures. ... even at the highest magnification. 3.5x, 4.5x ... precise color rendition is ideal for surgical ... coating produce a superior image. The compact ...
Medicine Products: